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ABSTRACT
This study investigated the clinical characteristics
of ciproﬂoxacin-resistant Proteus mirabilis isolates
from urine samples associated with nosocomial
infection or colonisation, and identiﬁed the risk-
factors for ciproﬂoxacin resistance. Data for
patients with ciproﬂoxacin-resistant P. mirabilis
isolates (n = 13) were compared with those for
randomly selected patients with ciproﬂoxacin-
susceptible P. mirabilis isolates (n = 40) who were
matched by temporal occurrence as control
patients. The majority of ciproﬂoxacin-resistant
P. mirabilis isolates were multiresistant, and cip-
roﬂoxacin resistance was associated signiﬁcantly
with previous use of ﬂuoroquinolones and
production of extended-spectrum b-lactamases.
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Fluoroquinolones are potent antimicrobial
agents that are used in the treatment of a wide
range of community-acquired and nosocomial
infections. However, resistance to ﬂuoroquino-
lones has increased signiﬁcantly since the late
1980s [1], and it has been demonstrated that use
of ﬂuoroquinolones is an important risk-factor
for ciproﬂoxacin resistance in Escherichia coli and
Klebsiella pneumoniae [2,3]. In addition, following
the worldwide use of broad-spectrum cephalo-
sporins during the past two decades, Gram-
negative bacteria producing extended-spectrum
b-lactamases (ESBLs) have emerged. This
emerging resistance is of great concern because
its association with resistance to other unrelated
antimicrobial agents severely limits therapeutic
options [2].
Proteus mirabilis is one of the most common
causes of urinary tract infection, and infections
caused by this organism are often nosocomial,
persistent and difﬁcult to treat. Although wild-
type strains of P. mirabilis are usually susceptible
to ﬂuoroquinolones and b-lactams, a progressive
increase in resistance to ﬂuoroquinolones and
broad-spectrum cephalosporins has been seen in
clinical isolates of this species [4–6]. The relation-
ship between ﬂuoroquinolone resistance and
ESBL production in E. coli and K. pneumoniae is
now well-known [3,7,8], but the epidemiology of
ﬂuoroquinolone resistance and its relationship
with ESBL production in P. mirabilis has not yet
been clariﬁed. The present study therefore inves-
tigated the clinical characteristics of ciproﬂoxacin-
resistant P. mirabilis isolates from urine and
identiﬁed the risk-factors for ciproﬂoxacin
resistance.
The study was conducted at a 1193-bed teach-
ing hospital, providing care for up to 1 million
individuals, between April 2003 and March 2006.
The medical records of patients were reviewed
retrospectively, and all patients with P. mirabilis
isolated from urine were enrolled in the study. An
infectious disease physician evaluated all patients
and classiﬁed the P. mirabilis isolates according to
CDC criteria for nosocomial infection [9]. Coloni-
sation was deﬁned when these criteria were not
fulﬁlled. Analysis results for consecutive urine
samples containing ‡105 CFU ⁄mL with pyuria
(‡10 leukocytes ⁄high-power ﬁeld) were obtained
from medical records. Data were also obtained for
patients with ciproﬂoxacin-resistant P. mirabilis
isolates and for randomly selected patients with
ciproﬂoxacin-susceptible P. mirabilis isolates, who
were matched by temporal occurrence as control
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patients. Data recorded were age, gender, under-
lying disease, date of hospitalisation, presence of
a urinary catheter or a central venous catheter,
and antibiotic therapy within the preceding
90 days.
All isolates were identiﬁed using the Vitek I
system (bioMe´rieux, Tokyo, Japan). Susceptibility
to ciproﬂoxacin, levoﬂoxacin, minocycline,
ampicillin, ampicillin–sulbactam, piperacillin,
ceftazidime, cefotaxime, aztreonam, amikacin,
gentamicin, imipenem and meropenem was
tested using panels manufactured by Eiken
Chemical (Tokyo, Japan). Nalidixic acid (Wako
Pure Chemical Industries, Osaka, Japan) was
also used. MICs were determined by broth micro-
dilution [10]. Quality control organisms for
susceptibility tests were Staphylococcus aureus
ATCC 21293, E. coliATCC 25922 and Pseudomonas
aeruginosa ATCC 27853. ESBL production was
initially detected using cefotaxime and cefotax-
ime–clavulanate disks, with ESBL-producing
P. mirabilis isolates being further screened for
the presence of class A b-lactamase genes (blaTEM,
blaSHV and blaCTX-M) by PCR using the primer sets
described previously [11,12]. Puriﬁed PCR frag-
ments were sequenced using an ABI Prism 310
DNA sequencer (Applied Biosystems, Foster City,
CA, USA), followed by a similarity search using
the BLAST program (DDBJ, Shizuoka, Japan).
Clonal relationships among ciproﬂoxacin-resis-
tant P. mirabilis isolates were investigated by
pulsed-ﬁeld gel electrophoresis following diges-
tion of chromosomal DNA using NotI (Roche
Diagnostics, Tokyo, Japan). Data were analysed
using JMP software, v.6.0 (SAS Institute, Tokyo,
Japan) and categorical variables were compared
by means of either the chi-square test or Fisher’s
exact test, as appropriate. A two-tailed p value of
<0.05 was considered to be signiﬁcant.
Among the 80 non-repetitive P. mirabilis isolates
from urine samples, 13 (16%) were ciproﬂoxacin-
resistant. Of the 13 patients involved, three (23%)
were classiﬁed as being infected, compared
with seven (18%) of 40 control patients (not
signiﬁcant). The antibiotic susceptibilities of the
P. mirabilis isolates are shown in Table 1. The
ciproﬂoxacin-resistant isolates showed a sig-
niﬁcantly higher frequency of resistance to
ampicillin, piperacillin, ampicillin–sulbactam,
cefotaxime, nalidixic acid and levoﬂoxacin
(p <0.001). Univariate analysis revealed that
previous use of ﬂuoroquinolones (p 0.042) and
ESBL production (p <0.001) were associated sig-
niﬁcantly with ciproﬂoxacin resistance (Table 1).
Eight isolates produced a CTX-M-2 ESBL. Eleven
genotypes were identiﬁed by pulsed-ﬁeld gel
electrophoresis among the 13 ciproﬂoxacin-resis-
tant P. mirabilis isolates, with three isolates being
clonally related.
Infections caused by ﬂuoroquinolone-resistant
ESBL-producing E. coli and K. pneumoniae strains
have now been reported throughout the world. It
has also been demonstrated that 18–56% of ESBL-
producing E. coli and K. pneumoniae strains are
resistant to ﬂuoroquinolones, and that ﬂuoro-
quinolone resistance is associated closely with
ESBL production [3,7,8]. Another cause for concern
is a marked increase in the incidence of P. mirabilis
isolates that are resistant to ﬂuoroquinolones and
broad-spectrum cephalosporins [4–6]. Previous
studies have demonstrated that ESBL-producing
isolates are usually resistant to penicillins, cepha-
losporins, aminoglycosides and trimethoprim–
sulphamethoxazole [3,6]. The present study
revealed that the majority of ciproﬂoxacin-resistant
P. mirabilis isolates from urine samples were mul-
tiresistant, with most being resistant to cefotaxime
and levoﬂoxacin, but not to aminoglycosides.
Table 1. Antibiotic suceptibilities and risk-factors for
Proteus mirabilis isolates from 13 patients (cases) with
ciproﬂoxacin-resistant isolates and 40 patients (controls)
with ciproﬂoxacin-susceptible isolates
Cases
(n = 13)
Controls
(n = 40) p
Antibiotic resistance frequency, n (%)
Ampicillin 11 (85) 1 (3) <0.001
Piperacillin 8 (62) 0 <0.001
Ampicillin–sulbactam 11 (85) 0 <0.001
Ceftazidime 0 0 NS
Cefotaxime 8 (62) 0 <0.001
Aztreonam 1 (8) 0 NS
Gentamicin 0 0 NS
Amikacin 0 0 NS
Imipenem 0 0 NS
Meropenem 0 0 NS
Minocycline 11 (85) 25 (63) NS
Nalidixic acid 13 (100) 9 (23) <0.001
Levoﬂoxacin 8 (62) 0 <0.001
Risk-factors, n (%)
Age, median years (range) 73 (53–91) 65 (3–94) NS
Male 7 (54) 14 (35) NS
Diabetes mellitus 3 (23) 9 (23) NS
Urinary catheter 6 (46) 18 (45) NS
Central venous catheter 3 (23) 5 (13) NS
Long hospital stay (>2 weeks) 5 (38) 14 (35) NS
ESBL production 8 (62) 0 <0.001
Use of other antibiotics within the previous
90 days
7 (54) 12 (30) NS
Cephems 1 (8) 8 (20) NS
Penicillins 2 (15) 1 (3) NS
Aminoglycosides 1 (8) 1 (3) NS
Fluoroquinolones 3 (23) 1 (3) 0.042
Carbapenems 2 (15) 2 (5) NS
ESBL, extended-spectrum b-lactamase; NS, not signiﬁcant.
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In the present study, acquisition of ciproﬂoxa-
cin resistance by P. mirabilis was found to be
associated signiﬁcantly with previous use of
ﬂuoroquinolones and ESBL production, as was
also found for ESBL-producing E. coli and
K. pneumoniae [3,7,8]. While the basis for com-
bined ciproﬂoxacin and broad-spectrum cephalo-
sporin resistance is not yet fully understood, the
presence of both ciproﬂoxacin resistance and
ESBL production may be a consequence of the
interplay of previous heavy antibiotic use and
conditions that favour patient-to-patient transfer
of multidrug-resistant organisms [3]. Other
possible explanations include active efﬂux,
outer-membrane alterations and ciproﬂoxacin
resistance mediated by plasmids containing a
class A b-lactamase gene.
In conclusion, the present study has certain
limitations, in that it was retrospective and sam-
ple numbers were small. However, the ciproﬂox-
acin-resistant P. mirabilis isolates also exhibited
multiresistance, and an analysis of risk-factors
showed that previous use of ﬂuoroquinolones
and ESBL production were the strongest deter-
minants of the acquisition of ciproﬂoxacin resis-
tance by P. mirabilis. Therefore, when treatment
protocols are designed for patients following the
isolation of ciproﬂoxacin-resistant P. mirabilis
from urine samples, the prevalence of ESBL-
producing strains should be taken into consider-
ation, and empirical antibiotic treatments with
greater efﬁcacy should be selected accordingly.
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